Strategic Partnerships NeuraLight has established and expanded collaborations with CHDI Foundation and other neuroscience-focused entities, signaling a strong track record in partnering for clinical endpoints and biomarker validation. Sales opportunities exist in expanding allied research collaborations and integrating NeuraLight’s brain function measurement platform into more neurodegenerative trial programs.

Clinical Trial Focus Active involvement in Huntington's disease and Parkinson's disease trials, along with eye movement biomarker development, indicates a deep market need for precise, scalable biomarkers. There is potential to upsell to pharmaceutical and biotech sponsors seeking objective, digital endpoints to accelerate trial timelines and improve endpoint sensitivity.

Recognition & Credibility Industry recognition as a finalist for Prix Galien USA Award in Digital Health and endorsements from neurologists and Nobel laureates bolster credibility. Leverage this to shorten assessment cycles with potential customers and to justify pilot programs and referenceable case studies.

Expansion Readiness Recent leadership addition to the Scientific Advisory Board and a Copenhagen presence suggest readiness for European market expansion and broader global trials. Opportunities include localization, regulatory alignment support, and channel partnerships to access multinational clinical programs.

Funding & Growth Signal Current revenue range and substantial funding indicate a scalable platform with growing customer adoption. This aligns with a target for mid-market pharma/biotech clients seeking evidence-grade digital biomarkers and scalable SaaS solutions for neurology trials.